Literature DB >> 20974247

Interactions between chemokine and mu-opioid receptors: anatomical findings and electrophysiological studies in the rat periaqueductal grey.

Silke Heinisch1, Jonathan Palma, Lynn G Kirby.   

Abstract

Opioids have immunomodulatory functions and may alter susceptibility to immune disorders. Behavioral studies also indicate that chemokines, molecules expressed by immune cells, block opioid-induced analgesia in the periaqueductal grey (PAG). Bi-directional heterologous desensitization of opioid and chemokine receptors has been described in cell systems. We report the anatomical and functional interactions of chemokine receptors with the mu-opioid receptor (MOR) in the rat brain. The chemokine receptors, CXCR4 and CX3CR1, as well as their chemokine substrates, CXCL12 and CX3CL1, are widely expressed in the central nervous system (CNS). Immunohistochemical techniques were utilized to investigate MOR-CXCR4 and MOR-CX3CR1 receptor colocalization in multiple brain areas. Our results demonstrate co-expression of these receptors on individual neurons in several regions including cingulate cortex, hippocampus, and PAG, suggesting functional receptor interactions. Whole-cell patch-clamp recordings of PAG neurons in a rat brain slice preparation were used to examine morphine or chemokine (CXCL12, CX3CL1) effects alone, or in combination on neuronal membrane properties. Morphine (10 μM) hyperpolarized and reduced input resistance of PAG neurons. CXCL12 and CX3CL1 (10 nM) had no impact on either parameter. In the presence of CXCL12, morphine's electrophysiological effects were blocked in all neurons examined, whereas with CX3CL1, morphine's effects were blocked in 57% of neurons studied. The data provide electrophysiological evidence for MOR-CXCR4 and MOR-CX3CR1 heterologous desensitization in the PAG at the single-cell level. These interactions may contribute to the limited utility of opioid analgesics for inflammatory pain treatment and supports chemokines as neuromodulators. Copyright Â
© 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20974247      PMCID: PMC3025063          DOI: 10.1016/j.bbi.2010.10.020

Source DB:  PubMed          Journal:  Brain Behav Immun        ISSN: 0889-1591            Impact factor:   7.217


  73 in total

Review 1.  Interactions between opioid and chemokine receptors: heterologous desensitization.

Authors:  Amber D Steele; Imre Szabo; Filip Bednar; Thomas J Rogers
Journal:  Cytokine Growth Factor Rev       Date:  2002-06       Impact factor: 7.638

Review 2.  Chemokine receptors: signposts to brain development and disease.

Authors:  Phuong B Tran; Richard J Miller
Journal:  Nat Rev Neurosci       Date:  2003-06       Impact factor: 34.870

Review 3.  Chemokine receptors in inflammation: an overview.

Authors:  Daniele D'Ambrosio; Paola Panina-Bordignon; Francesco Sinigaglia
Journal:  J Immunol Methods       Date:  2003-02       Impact factor: 2.303

4.  Electrophysiological and pharmacological characterization of serotonergic dorsal raphe neurons recorded extracellularly and intracellularly in rat brain slices.

Authors:  C P Vandermaelen; G K Aghajanian
Journal:  Brain Res       Date:  1983-12-19       Impact factor: 3.252

5.  Selective inactivation of CCR5 and decreased infectivity of R5 HIV-1 strains mediated by opioid-induced heterologous desensitization.

Authors:  Imre Szabo; Michele A Wetzel; Ning Zhang; Amber D Steele; David E Kaminsky; Chongguang Chen; Lee-Yuan Liu-Chen; Filip Bednar; Earl E Henderson; O M Zack Howard; Joost J Oppenheim; Thomas J Rogers
Journal:  J Leukoc Biol       Date:  2003-09-12       Impact factor: 4.962

6.  CXCR4 regulates interneuron migration in the developing neocortex.

Authors:  Ralf K Stumm; Chun Zhou; Toshiaki Ara; Françoise Lazarini; Monique Dubois-Dalcq; Takashi Nagasawa; Volker Höllt; Stefan Schulz
Journal:  J Neurosci       Date:  2003-06-15       Impact factor: 6.167

7.  Production and neuroprotective functions of fractalkine in the central nervous system.

Authors:  Tetsuya Mizuno; Jun Kawanokuchi; Kenji Numata; Akio Suzumura
Journal:  Brain Res       Date:  2003-07-25       Impact factor: 3.252

8.  Heterodimerization and cross-desensitization between the mu-opioid receptor and the chemokine CCR5 receptor.

Authors:  Chongguang Chen; Jin Li; George Bot; Imre Szabo; Thomas J Rogers; Lee-Yuan Liu-Chen
Journal:  Eur J Pharmacol       Date:  2004-01-12       Impact factor: 4.432

9.  Fractalkine (CX3CL1) and fractalkine receptor (CX3CR1) distribution in spinal cord and dorsal root ganglia under basal and neuropathic pain conditions.

Authors:  Gail M Verge; Erin D Milligan; Steve F Maier; Linda R Watkins; Gregory S Naeve; Alan C Foster
Journal:  Eur J Neurosci       Date:  2004-09       Impact factor: 3.386

10.  Proinflammatory chemokines, such as C-C chemokine ligand 3, desensitize mu-opioid receptors on dorsal root ganglia neurons.

Authors:  Ning Zhang; Thomas J Rogers; Michael Caterina; Joost J Oppenheim
Journal:  J Immunol       Date:  2004-07-01       Impact factor: 5.422

View more
  29 in total

1.  Spinal CX3CL1/CX3CR1 May Not Directly Participate in the Development of Morphine Tolerance in Rats.

Authors:  Yawen Peng; Genhua Guo; Bin Shu; Daiqiang Liu; Peng Su; Xuming Zhang; Feng Gao
Journal:  Neurochem Res       Date:  2017-08-03       Impact factor: 3.996

Review 2.  CXCL12 signaling in the development of the nervous system.

Authors:  Divakar S Mithal; Ghazal Banisadr; Richard J Miller
Journal:  J Neuroimmune Pharmacol       Date:  2012-01-21       Impact factor: 4.147

Review 3.  Opioid-induced central immune signaling: implications for opioid analgesia.

Authors:  Peter M Grace; Steven F Maier; Linda R Watkins
Journal:  Headache       Date:  2015-03-31       Impact factor: 5.887

Review 4.  Mechanisms of acupuncture-electroacupuncture on persistent pain.

Authors:  Ruixin Zhang; Lixing Lao; Ke Ren; Brian M Berman
Journal:  Anesthesiology       Date:  2014-02       Impact factor: 7.892

5.  Chemokine Receptor Antagonists in Combination with Morphine as a Novel Strategy for Opioid Dose Reduction in Pain Management.

Authors:  Toby K Eisenstein; Xiaohong Chen; Saadet Inan; Joseph J Meissler; Christopher S Tallarida; Ellen B Geller; Scott M Rawls; Alan Cowan; Martin W Adler
Journal:  Mil Med       Date:  2020-01-07       Impact factor: 1.437

6.  The triplet puzzle theory indicates extensive formation of heteromers between opioid and chemokine receptor subtypes.

Authors:  Alexander O Tarakanov; Kjell Fuxe
Journal:  J Neural Transm (Vienna)       Date:  2015-07-02       Impact factor: 3.575

7.  The effect of gp120 on morphine's antinociceptive and neurophysiological actions.

Authors:  Xiaohong Chen; Lynn G Kirby; Jonathan Palma; Khalid Benamar; Ellen B Geller; Toby K Eisenstein; Martin W Adler
Journal:  Brain Behav Immun       Date:  2011-05-05       Impact factor: 7.217

Review 8.  In vivo opioid receptor heteromerization: where do we stand?

Authors:  D Massotte
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

9.  Differential expression of the alternatively spliced OPRM1 isoform μ-opioid receptor-1K in HIV-infected individuals.

Authors:  Seth M Dever; Blair N Costin; Ruqiang Xu; Nazira El-Hage; Joyce Balinang; Alexander Samoshkin; Megan A O'Brien; Marypeace McRae; Luda Diatchenko; Pamela E Knapp; Kurt F Hauser
Journal:  AIDS       Date:  2014-01-02       Impact factor: 4.177

Review 10.  Functions of the chemokine receptor CXCR4 in the central nervous system and its regulation by μ-opioid receptors.

Authors:  Bradley Nash; Olimpia Meucci
Journal:  Int Rev Neurobiol       Date:  2014       Impact factor: 3.230

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.